Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) EBT (2021 - 2025)

Historic EBT for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$51.0 million.

  • Rxo's EBT fell 5454.55% to -$51.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$115.0 million, marking a year-over-year increase of 6217.11%. This contributed to the annual value of -$115.0 million for FY2025, which is 6217.11% up from last year.
  • According to the latest figures from Q4 2025, Rxo's EBT is -$51.0 million, which was down 5454.55% from -$15.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's EBT ranged from a high of $59.0 million in Q2 2022 and a low of -$242.0 million during Q3 2024
  • Its 5-year average for EBT is -$11.3 million, with a median of -$4.5 million in 2022.
  • In the last 5 years, Rxo's EBT surged by 16666.67% in 2023 and then plummeted by 796666.67% in 2024.
  • Rxo's EBT (Quarter) stood at $55.0 million in 2021, then plummeted by 110.91% to -$6.0 million in 2022, then skyrocketed by 166.67% to $4.0 million in 2023, then plummeted by 925.0% to -$33.0 million in 2024, then crashed by 54.55% to -$51.0 million in 2025.
  • Its EBT stands at -$51.0 million for Q4 2025, versus -$15.0 million for Q3 2025 and -$10.0 million for Q2 2025.